<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438736</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2011-001492-39</org_study_id>
    <secondary_id>IIPS#39689</secondary_id>
    <nct_id>NCT01438736</nct_id>
  </id_info>
  <brief_title>Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?</brief_title>
  <official_title>A Randomized Study to Evaluate the Predictive Impact of Using Cerazette Progestin Only Pill Before Nexplanon Insertion Regarding Bleeding Pattern</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VL-Medi Oy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VL-Medi Oy</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine how well three months preceding use of Cerazette
      progestin only pill predicts the bleeding pattern during following Nexplanon implant use.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total number of bleeding days per 90 days reference period in women using Cerazette before Nexplanon and in women starting Nexplanon without preceding POP</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of bleeding episodes according to WHO definitions</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Desogestrel, Etonogestrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etonogestrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: Women staring straight with Nexplanon implant for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)</intervention_name>
    <description>Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months</description>
    <arm_group_label>Desogestrel, Etonogestrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel 68 mg subdermal implant</intervention_name>
    <description>Etonogestrel 68 mg subdermal implant for 6 months</description>
    <arm_group_label>Etonogestrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women, 18-40 years of age

          -  regular menstrual cycle (period 23-35 days)

        Exclusion Criteria:

          -  -Immediate previous use of progestin only contraception within 2 months

          -  Known or suspected pregnancy

          -  Acute tromboembolic disorder

          -  Presence or history of hepatic disease, as long as the liver function values have not
             returned to normal

          -  Undiagnosed vaginal bleeding

          -  Known or suspected sex-steroid influenced malignancies (e.g. breast cancer)

          -  Hypersensitivity to the active substances or to any of the excipients of the medicines

          -  Pregnant or breast feeding within 6 weeks

          -  The use of other medicinal products that might interact with contraceptive steroids
             and affect the efficacy of contraceptives and/or might may lead to bleeding
             irregularities (especially medicines that induce the liver enzyme systems such as
             cytochrome P450). Examples of active substances are: phenytoin, phenobarbital,
             primidone, bosentan, carbamatzepine, rifampicin and medicinal products or herbal
             preparations containing ST.John's wort and to a lesser extend oxcarbazepine,
             topiramate, felbamate and griseofulvin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Apter, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>VL-Medi Oy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Apter, Docent</last_name>
    <phone>+358405550842</phone>
    <email>dan.apter@vaestoliitto.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>VL Medi Oy</name>
      <address>
        <city>Helsinki</city>
        <zip>00101</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dan Apter, docent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Focus:</keyword>
  <keyword>preceding</keyword>
  <keyword>desogestrel predicts</keyword>
  <keyword>pattern of following</keyword>
  <keyword>etonogestrel implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

